PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Nguyen, N.T.T.* ; Müller, R.* ; Briukhovetska, D.* ; Weber, J.* ; Feucht, J.* ; Künkele, A.* ; Hudecek, M.* ; Kobold, S.

The spectrum of CAR cellular effectors: Modes of action in anti-tumor immunity.

Cancers 16:2608 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Chimeric antigen receptor-T cells have spearheaded the field of adoptive cell therapy and have shown remarkable results in treating hematological neoplasia. Because of the different biology of solid tumors compared to hematological tumors, response rates of CAR-T cells could not be transferred to solid entities yet. CAR engineering has added co-stimulatory domains, transgenic cytokines and switch receptors to improve performance and persistence in a hostile tumor microenvironment, but because of the inherent cell type limitations of CAR-T cells, including HLA incompatibility, toxicities (cytokine release syndrome, neurotoxicity) and high costs due to the logistically challenging preparation process for autologous cells, the use of alternative immune cells is gaining traction. NK cells and γδ T cells that do not need HLA compatibility or macrophages and dendritic cells with additional properties such as phagocytosis or antigen presentation are increasingly seen as cellular vehicles with potential for application. As these cells possess distinct properties, clinicians and researchers need a thorough understanding of their peculiarities and commonalities. This review will compare these different cell types and their specific modes of action seen upon CAR activation.
Impact Factor
Scopus SNIP
Altmetric
4.500
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Adoptive Cell Therapy ; Chemokines ; Chimeric Antigen Receptor ; Cytokines ; Dendritic Cells ; Gamma-delta T Cells ; Killing Mechanism ; Kinetics ; Macrophages ; Mode Of Action ; Natural Killer Cells ; Persistence; Natural-killer-cells; Chimeric Antigen Receptor; V-gamma-9v-delta-2 T-cells; Pluripotent Stem-cells; Fc-gamma Receptors; Dendritic Cells; Fas Ligand; Nk-cell; B-cell; Adoptive Immunotherapy
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 2072-6694
Zeitschrift Cancers
Quellenangaben Band: 16, Heft: 14, Seiten: , Artikelnummer: 2608 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-522100-001
Förderungen Monika Kutzner Foundation
Ernst Jung Stiftung
Wilhelm-Sander-Stiftung
German Cancer Aid (AvantCAR.de)
Else Kroner-Fresenius-Stiftung (IOLIN)
Horizon 2020 program of the European Union
Melanoma Research Alliance
Elite Network of Bavaria
Deutsche Forschungsgemeinschaft (DFG)
Institutional Strategy LMUexcellent of LMU Munich (within the framework of the German Excellence Initiative)
Bavarian Ministry for Economical Affairs
Bundesministerium fur Bildung und Forschung
Bruno and Helene Joster Foundation
Bavarian Research Foundation
Hector Foundation
Deutsche JoseCarreras Leukamie Stiftung
Fritz-Bender Foundation
SFB-TRR
European Research Council
Bavarian Cancer Research Center (BZKF)
DOI 10.3390/cancers16142608
WOS ID 001276673000001
Scopus ID 85199648100
PubMed ID 39061247
Erfassungsdatum 2024-08-01
[➜Korrektur melden]